Search

Your search keyword '"Recher, C"' showing total 426 results
Start Over Author "Recher, C"
426 results on '"Recher, C"'

5. Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study

Author

Krug, U, Ravandi, F, Ritchie, EK, Sayar, H, Lancet, JE, Craig, MD, Vey, N, Strickland, SA, Schiller, GJ, Jabbour, E, Erba, HP, Pigneux, A, Horst, H-A, Recher, C, Klimek, VM, Cortes, J, Roboz, GJ, Craig, AR, Fox, JA, Ward, R, Smith, JA, Acton, G, Mehta, C, Kantarjian, HM, and Stuart, RK

Published
2015

6. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults

Author

Piel‐Julian, M.‐L., Mahévas, M., Germain, J., Languille, L., Comont, T., Lapeyre‐Mestre, M., Payrastre, B., Beyne‐Rauzy, O., Michel, M., Godeau, B., Adoue, D., Moulis, G., Alric, L., Arista, S., Astudillo, L., Balardy, L., Betrian, S., Bonnet, D., Borel, C., Brechemier, D., Brun, N., Carreiro, M., Castel, B., Caudrelier, L., Cougoul, P., Danu, A., Delavigne, K., Dingremont, C., Faurie, T., Gaches, F., Gaspard, M.‐H., Gaudin, C., Godel‐Labouret, A., Giraud, P., Hadj‐Khelifa, S., Hebraud, B., Khatibi, S., Leplay, L., Leveneur, Y., Limal, N., Ollier, S., Madaule, S., Marchou, B., Martel, C., Martin‐Blondel, G., Montane De La Roque, P., Michaud, M., Moeglin, J., Nuccio, F., Prudhomme, L., Pugnet, G., Recher, C., Remy, V., Sailler, L., Sire, S., Sommet, A., Tavitian, S., Thiercelin‐Legrand, M.‐F., and Vaillant, W.

Published
2018
Full Text
View/download PDF

9. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib

Author

Perl, AE, Perl, AE, Hosono, N, Montesinos, P, Podoltsev, N, Martinelli, G, Panoskaltsis, N, Recher, C, Smith, CC, Levis, MJ, Strickland, S, Röllig, C, Groß-Langenhoff, M, Chou, WC, Lee, JH, Yokoyama, H, Hasabou, N, Lu, Q, Tiu, RV, Altman, JK, Perl, AE, Perl, AE, Hosono, N, Montesinos, P, Podoltsev, N, Martinelli, G, Panoskaltsis, N, Recher, C, Smith, CC, Levis, MJ, Strickland, S, Röllig, C, Groß-Langenhoff, M, Chou, WC, Lee, JH, Yokoyama, H, Hasabou, N, Lu, Q, Tiu, RV, and Altman, JK

Abstract

The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), based on its observed superior response and survival outcomes compared with salvage chemotherapy (SC). Frontline use of FLT3 tyrosine kinase inhibitors (TKIs) midostaurin and sorafenib may contribute to cross-resistance to single-agent gilteritinib in the R/R AML setting but has not been well characterized. To clarify the potential clinical impact of prior TKI use, we retrospectively compared clinical outcomes in patients with R/R FLT3-mutated AML in the CHRYSALIS and ADMIRAL trials who received prior midostaurin or sorafenib against those without prior FLT3 TKI exposure. Similarly high rates of composite complete remission (CRc) were observed in patients who received a FLT3 TKI before gilteritinib (CHRYSALIS, 42%; ADMIRAL, 52%) and those without prior FLT3 TKI therapy (CHRYSALIS, 43%; ADMIRAL, 55%). Among patients who received a prior FLT3 TKI in ADMIRAL, a higher CRc rate (52%) and trend toward longer median overall survival was observed in the gilteritinib arm versus the SC arm (CRc = 20%; overall survival, 5.1 months; HR = 0.602; 95% CI: 0.299, 1.210). Remission duration was shorter with prior FLT3 TKI exposure. These findings support gilteritinib for FLT3-mutated R/R AML after prior sorafenib or midostaurin.

Published
2022

10. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Author

Pratz, KW, Panayiotidis, P, Recher, C, Wei, X, Jonas, BA, Montesinos, P, Ivanov, V, Schuh, AC, DiNardo, CD, Novak, J, Pejsa, V, Stevens, D, Yeh, S-P, Kim, I, Turgut, M, Fracchiolla, N, Yamamoto, K, Ofran, Y, Wei, AH, Bui, CN, Benjamin, K, Kamalakar, R, Potluri, J, Mendes, W, Devine, J, Fiedler, W, Pratz, KW, Panayiotidis, P, Recher, C, Wei, X, Jonas, BA, Montesinos, P, Ivanov, V, Schuh, AC, DiNardo, CD, Novak, J, Pejsa, V, Stevens, D, Yeh, S-P, Kim, I, Turgut, M, Fracchiolla, N, Yamamoto, K, Ofran, Y, Wei, AH, Bui, CN, Benjamin, K, Kamalakar, R, Potluri, J, Mendes, W, Devine, J, and Fiedler, W

Abstract

Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P < 0.001). VEN + LDAC vs PBO + LDAC patients had significantly longer TTD in GHS/QoL (P = 0.011), PF (P = 0.020), and fatigue (P = 0.004), and a trend in HS-VAS (P = 0.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN + AZA, AZA + PBO, VEN + LDAC, or LDAC + PBO, respectively, saw improvements >MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.

Published
2022

11. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia

Author

Jonas, BA, Wei, AH, Recher, C, DiNardo, CD, Jang, J-H, Pratz, K, Panayiotidis, P, Montesinos, P, Yeh, S-P, Ivanov, V, Fiedler, W, Yamauchi, T, Duan, Y, Mendes, W, Potluri, J, Tews, B, Ofran, Y, Jonas, BA, Wei, AH, Recher, C, DiNardo, CD, Jang, J-H, Pratz, K, Panayiotidis, P, Montesinos, P, Yeh, S-P, Ivanov, V, Fiedler, W, Yamauchi, T, Duan, Y, Mendes, W, Potluri, J, Tews, B, and Ofran, Y

Published
2022

12. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma

Author

Morschhauser, F., Recher, C., Milpied, N., Gressin, R., Salles, G., Brice, P., Vey, N., Haioun, C., Colombat, P., Rossi, J.F., Deconinck, E., Lazreg, F., Bergougnoux, L., Delsol, G., and Attal, M.

Published
2012
Full Text
View/download PDF

13. P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA

Author

Dohner, H., primary, Montesinos, P., additional, Vives Polo, S., additional, Zarzycka, E., additional, Wang, J., additional, Bertani, G., additional, Heuser, M., additional, Calado, R., additional, Schuh, A., additional, Yeh, S.-P., additional, de la Fuente, A., additional, Cerchione, C., additional, Daigle, S., additional, Hui, J., additional, Pandya, S., additional, Gianolio, D., additional, Recher, C., additional, and de Botton, S., additional

Published
2022
Full Text
View/download PDF

14. P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE

Author

de Botton, S., primary, Choe, S., additional, Marchione, D., additional, Montesinos, P., additional, Recher, C., additional, Vives Polo, S., additional, Zarzycka, E., additional, Wang, J., additional, Bertani, G., additional, Heuser, M., additional, Calado, R., additional, Schuh, A., additional, Yeh, S.-P., additional, Hui, J., additional, Pandya, S., additional, Gianolio, D., additional, Daigle, S., additional, DiNardo, C., additional, and Dohner, H., additional

Published
2022
Full Text
View/download PDF

15. P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD123-POSITIVE AML

Author

Daver, N. G., primary, Montesinos, P., additional, Aribi, A., additional, Martinelli, G., additional, Altman, J., additional, Roboz, G., additional, Wang, E. S., additional, Burke, P. W., additional, Jeyakumar, D., additional, Walter, R. B., additional, DeAngelo, D. J., additional, Erba, H. P., additional, Advani, A., additional, Gastaud, L., additional, Thomas, X., additional, Todisco, E., additional, Pemmaraju, N., additional, Mendez, L., additional, de la Fuente, A., additional, Gaidano, G., additional, Curti, A., additional, Boissel, N., additional, Recher, C., additional, Schliemann, C., additional, Vyas, P., additional, Sloss, C. M., additional, Wang, J., additional, Malcolm, K. A., additional, Zweidler-McKay, P. A., additional, and Sweet, K. L., additional

Published
2022
Full Text
View/download PDF

16. P477: PHENOTYPICALLY-DEFINED STAGES OF LEUKEMIA ARREST PREDICT MAIN DRIVER MUTATIONS SUBGROUPS, AND OUTCOME IN ACUTE MYELOID LEUKEMIA

Author

Vergez, F., primary, Largeaud, L., additional, Bertoli, S., additional, Nicolau-Travers, M.-L., additional, Rieu, J.-B., additional, Vergnolle, I., additional, Saland, E., additional, Sarry, A., additional, Tavitian, S., additional, Huguet, F., additional, Picard, M., additional, Vial, J.-P., additional, Lechevalier, N., additional, Bidet, A., additional, Dumas, P.-Y., additional, Pigneux, A., additional, Luquet, I., additional, Mansat-De Mas, V., additional, Delabesse, E., additional, Carroll, M., additional, Danet-Desnoyers, G., additional, Sarry, J.-E., additional, and Recher, C., additional

Published
2022
Full Text
View/download PDF

17. P556: CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE

Author

Schuh, A., primary, de Botton, S., additional, Recher, C., additional, Vives Polo, S., additional, Zarzycka, E., additional, Wang, J., additional, Bertani, G., additional, Heuser, M., additional, Calado, R., additional, Yeh, S.-P., additional, Hui, J., additional, Pandya, S., additional, Gianolio, D., additional, Chamberlain, C., additional, Dohner, H., additional, and Montesinos, P., additional

Published
2022
Full Text
View/download PDF

18. P510: THE IMPACT OF POST-REMISSION GRANULOCYTE COLONY-STIMULATING FACTOR USE IN THE PHASE 3 STUDIES OF VENETOCLAX COMBINATION TREATMENTS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

Author

DiNardo, C., primary, Pratz, K., additional, Panayiotidis, P., additional, Wei, X., additional, Vorobyev, V., additional, Illés, Á., additional, Kim, I., additional, Ivanov, V., additional, Ku, G., additional, Miller, C. L., additional, Zhang, M., additional, Tatsch, F., additional, Potluri, J., additional, Schmidt, X., additional, and Recher, C., additional

Published
2022
Full Text
View/download PDF

19. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Author

Pratz, K.W. Panayiotidis, P. Recher, C. Wei, X. Jonas, B.A. Montesinos, P. Ivanov, V. Schuh, A.C. DiNardo, C.D. Novak, J. Pejsa, V. Stevens, D. Yeh, S.-P. Kim, I. Turgut, M. Fracchiolla, N. Yamamoto, K. Ofran, Y. Wei, A.H. Bui, C.N. Benjamin, K. Kamalakar, R. Potluri, J. Mendes, W. Devine, J. Fiedler, W.

Subjects
humanities
Abstract

Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P < 0.001). VEN + LDAC vs PBO + LDAC patients had significantly longer TTD in GHS/QoL (P = 0.011), PF (P = 0.020), and fatigue (P = 0.004), and a trend in HS-VAS (P = 0.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN + AZA, AZA + PBO, VEN + LDAC, or LDAC + PBO, respectively, saw improvements >MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status. © 2022, The Author(s).

Published
2022

23. Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights

Author

Martin, J.E., Khalife-Hachem, S., Grinda, T., Kfoury, M., Garciaz, S., Pasquier, F., Vargaftig, J., Uzunov, M., Belhabri, A., Bertoli, S., Cotteret, S., Vergé, V., Renneville, A., Rosselli, F., Antony-Debre, I., Rouleau, E., Salviat, F., Caron, O., Delaloge, S., Pautier, P., Etienne, G., Recher, C., Vey, N., De Botton, S., Leary, A., Marzac, C., and Micol, J.B.

Published
2021
Full Text
View/download PDF

26. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF)

Author

Dupont, H., Marolleau, J.P., Totet, A., Damiani, C., Berceanu, A., Larosa, F., Bonhomme, J., Chabrot, C., Bouteille, B., Boutoille, D., Gastinne, T., Peterlin, P., Gari Toussaint, M., Poisson, D., Briet, D., Buret, J., Legrand, M., Denis, B., Raffoux, E., Bergeron, A., Veinstein, A., Godet, C., N'guyen, Y., Diallo, S., Sabou, M., Denis, J., Ledoux, M.P., Recher, C., Ruiz, J., Desoubeaux, G., Bailly, E., Chachaty, E., Dromer, F., Lortholary, O., Sitbon, K., Hoinard, D., Millon, L., Herbrecht, R., Grenouillet, F., Morio, F., Alanio, A., Letscher-Bru, V., Cassaing, S., Chouaki, T., Kauffmann-Lacroix, C., Poirier, P., Toubas, D., Augereau, O., Rocchi, S., Garcia-Hermoso, D., and Bretagne, S.

Published
2016
Full Text
View/download PDF

28. Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III

Author

Cluzeau, T., primary, Sebert, M., additional, Rahmé, R., additional, Cuzzubbo, S., additional, Walter-Petrich, A., additional, Peterlin, P., additional, Recher, C., additional, Stamatoullas, A., additional, Willems, L., additional, Raffoux, E., additional, Berthon, C., additional, Sallman, D., additional, Ades, L., additional, and Fenaux, P., additional

Published
2021
Full Text
View/download PDF

29. ELTROMBOPAG ADDED TO STANDARD IMMUNOSUPPRESSION IMPROVES RESPONSE RATE IN SEVERE APLASTIC ANEMIA: RESULTS OF THE MULTICENTER PHASE III PROSPECTIVE RANDOMIZED RACE TRIAL

Author

Risitano, AM, Kulasekararaj, A, Iacobelli, S, Terwel, S, Hill, A, Halkes, CJM, Recher, C, Barraco, F, Forcade, E, Llamas, JCV, Drexler, B, Mear, JB, Van Lint, MT, Raymakers, RAP, De Groot, MR, Daguindau, E, Nur, E, Barcellini, W, Russell, NH, Terriou, L, Iori, AP, Sanchez-Ortega, I, Xicoy, B, Jarque, I, Cavenagh, J, De Fontbrune, FS, Marotta, S, Munir, T, Tjon, JML, Tavitian, S, Praire, A, Clement, L, Rabian, F, Smith, AE, Cook, R, Marano, L, Griffin, M, Palmisani, E, Muus, P, Cacace, F, Frieri, C, Passweg, JR, Marsh, JCW, Socie, G, Mufti, GJ, Dufour, C, and de Latour, RP

Published
2021

30. Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis

Author

de Botton, S, Brandwein, JM, Wei, AH, Pigneux, A, Quesnel, B, Thomas, X, Legrand, O, Recher, C, Chantepie, S, Hunault-Berger, M, Boissel, N, Nehme, SA, Frattini, MG, Tosolini, A, Marion-Gallois, R, Wang, JJ, Cameron, C, Siddiqui, M, Hutton, B, Milkovich, G, Stein, EM, de Botton, S, Brandwein, JM, Wei, AH, Pigneux, A, Quesnel, B, Thomas, X, Legrand, O, Recher, C, Chantepie, S, Hunault-Berger, M, Boissel, N, Nehme, SA, Frattini, MG, Tosolini, A, Marion-Gallois, R, Wang, JJ, Cameron, C, Siddiqui, M, Hutton, B, Milkovich, G, and Stein, EM

Abstract

BACKGROUND: The present study evaluated the relative survival benefits associated with enasidenib and current standard of care (SoC) therapies for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and an isocitrate dehydrogenase 2 (IDH2) mutation who are ineligible for hematopoietic stem cell transplantation (HSCT). METHODS: Propensity score matching (PSM) analysis compared survival outcomes observed with enasidenib 100 mg daily in the phase I/II AG221-C-001 trial and SoC outcomes obtained from a real-world chart review of patients in France. RESULTS: Before matching, enasidenib (n = 195) was associated with numerically improved overall survival (OS) relative to SoC (n = 80; hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.61-1.11). After matching and adjusting for covariates (n = 78 per group), mortality risk was significantly lower with enasidenib than with SoC (HR, 0.67; 95% CI, 0.47-0.97). The median OS was 9.26 months for enasidenib (95% CI, 7.72-13.24) and 4.76 months for SoC (95% CI, 3.81-8.21). Results remained robust across all sensitivity analyses conducted. CONCLUSIONS: PSM analyses indicate that enasidenib significantly prolongs survival relative to SoC among patients with R/R AML and an IDH2 mutation who are ineligible for HSCT. Future prospective studies are needed to validate these findings using other data sources and to assess the comparative efficacy of enasidenib for other treatment outcomes.

Published
2021

33. Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial

Author

Chevallier, P, Fornecker, L, Lioure, B, Béné, M C, Pigneux, A, Recher, C, Witz, B, Fegueux, N, Bulabois, C-E, Daliphard, S, Bouscary, D, Vey, N, Delain, M, Bay, J-O, Turlure, P, Bernard, M, Himberlin, C, Luquet, I, Ifrah, N, and Harousseau, J-L

Published
2010
Full Text
View/download PDF

35. Results of the Ebmt Saawp Phase III Prospective Randomized Multicenter Race Study of Horse Atg and Ciclosporin with or Without Eltrombopag in Naive Saa Patients

Author

de Latour, RP, Marsh, J, Iacobelli, S, Terwel, S, Hill, A, Halkes, CJM, Recher, C, Barraco, F, Forcade, E, Llamas, JCV, Dresler, B, Mear, JB, Van Lint, MT, Raymakers, RAP, De Groot, MR, Daguindau, E, Nur, E, Barcellini, W, Russell, NH, Terriou, L, Iori, AP, Sanchez-Ortega, I, Xicoy, B, Jarque, I, Cavenagh, J, de Fontbrune, FS, Kulasekararaj, A, Marotta, S, Munir, T, Tjon, JML, Tavitian, S, Praire, A, Clement, L, Rabian, F, Smith, AE, Cook, R, Marano, L, Griffin, M, Palmisani, E, Muus, P, Cacace, F, Passweg, JR, Socie, G, Mufti, GJ, Dufour, C, and Risitano, A

Published
2020

36. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

Author

Rea, D, Legros, L, Raffoux, E, Thomas, X, Turlure, P, Maury, S, Dupriez, B, Pigneux, A, Choufi, B, Reman, O, Stéphane, D, Royer, B, Vigier, M, Ojeda-Uribe, M, Recher, C, Dombret, H, Huguet, F, and Rousselot, P

Published
2006
Full Text
View/download PDF

38. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia

Author

Terre, C, Eclache, V, Rousselot, P, Imbert, M, Charrin, C, Gervais, C, Mozziconacci, M J, Maarek, O, Mossafa, H, Auger, N, Dastugue, N, Talmant, P, Van den Akker, J, Leonard, C, Khac, F N'Guyen, Mugneret, F, Viguié, F, Lafage-Pochitaloff, M, Bastie, J N, Roux, G L, Nicolini, F, Maloisel, F, Vey, N, Laurent, G, Recher, C, Vigier, M, Yacouben, Y, Giraudier, S, Vernant, J P, Salles, B, Roussi, J, Castaigne, S, Leymarie, V, Flandrin, G, and Lessard, M

Published
2004
Full Text
View/download PDF

46. IDH1 Mutation Augments System-Level Metabolic Flexibility that Favors Mitochondrial Oxidative Phosphorylation and Drug Resistance in Acute Myeloid Leukemia

Author

Stuani, Lucille, Sabatier, M., Millard, Pierre, Recher, C.,, Portais, Jean-Charles, Sarry, J.E.,, Toulouse Biotechnology Institute (TBI), Institut National de la Recherche Agronomique (INRA)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS), and Université de Toulouse (UT)

Subjects
[SDV.BIO]Life Sciences [q-bio]/Biotechnology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

47. Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Author

Smith CC, Levis MJ, Perl AE, Martinelli G, Neubauer A, Berman E, Montesinos P, Baer MR, Larson RA, Chou WC, Yokoyama H, Recher C, Yoon SS, Hill JE, Rosales M, and Bahceci E

Abstract

Smith: Revolution Medicines: Research Funding; Astellas Pharma: Research Funding; fujiFilm: Research Funding; Abbvie: Research Funding. Levis:Astellas: Consultancy, Research Funding; FUJIFILM: Consultancy, Research Funding; Menarini: Consultancy, Honoraria; Novartis: Consultancy, Research Funding; Agios: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Daiichi Sankyo Inc: Consultancy, Honoraria. Perl:Astellas: Consultancy, Honoraria, Other: Non-financial support included travel costs for advisory board meetings as well as a medical writing company that assisted with manuscript preparation/submission and slide deck assembly for academic meeting presentations of trial data., Research Funding; BioMed Valley Discoveries: Research Funding; Daiichi Sankyo: Consultancy, Honoraria, Other, Research Funding; Arog: Consultancy, Other: Non-financial support included travel costs for advisory board meetings.; AbbVie: Consultancy, Honoraria, Other: Non-financial support included travel costs for advisory board meetings.; Actinium Pharmaceuticals: Consultancy, Honoraria, Other: Clinical Advisory Board member, Research Funding; Agios: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Non-financial support included travel costs for advisory board meetings.; Jazz: Consultancy, Honoraria, Other: Non-financial support included travel costs for advisory board meetings.; NewLink Genetics: Consultancy, Honoraria, Other: Non-financial support included travel costs for advisory board meetings.; Takeda: Consultancy, Honoraria, Other: Non-financial support included travel costs for advisory board meetings.; Bayer: Research Funding; FujiFilm: Research Funding; Novartis: Honoraria, Other: Advisory board, Non-financial support included travel costs for advisory board meetings as well as a medical writing company that assisted with manuscript preparation/submission and slide deck assembly for academic meeting presentations of the data., Research Funding. Martinelli:Daiichi Sankyo: Consultancy, Honoraria; Roche: Consultancy, Other: trial grant; Ariad: Consultancy, Other: trial grant; Janssen: Consultancy, Other: trial grant; Amgen: Consultancy, Other: trial grant; Pfizer: Consultancy, Other: trial grant; Abbvie: Consultancy, Honoraria, Other: trial grant; Celgene: Consultancy, Honoraria, Other: trial grant; Novartis: Consultancy, Other: trial grant; Incyte: Consultancy, Other: trial grant. Berman:Astellas: Membership on an entity's Board of Directors or advisory committees, Research Funding. Montesinos:Karyopharm: Membership on an entity's Board of Directors or advisory committees, Other: Research support; Pfizer: Membership on an entity's Board of Directors or advisory committees, Other: Research support, Research Funding, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Research support, Speakers Bureau; Teva: Membership on an entity's Board of Directors or advisory committees, Other: Research support, Research Funding, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Research support, Research Funding, Speakers Bureau; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Research support, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Research support, Research Funding, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Baer:Abbvie: Research Funding; Astellas: Research Funding; Al Therapeutics: Research Funding; Forma: Research Funding; Incyte: Research Funding; Kite: Research Funding; Takeda: Research Funding. Larson:Celgene: Consultancy; Agios: Consultancy; Novartis: Honoraria, Other: Contracts for clinical trials. Yokoyama:Astellas: Other: Travel expenses. Recher:Incyte: Honoraria; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sunesis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; Macrogenics: Consultancy, Membership on an entity's Board of Directors or advisory committees. Yoon:MSD: Consultancy; Kyowa Hako Kirin: Research Funding; Janssen: Consultancy; Genentech, Inc.: Research Funding; Amgen: Consultancy, Honoraria; Yuhan Pharma: Research Funding; Novartis: Consultancy, Honoraria. Hill:Astellas: Employment; Ligacept, LLC.: Other: Stock, Patents Royalties. Rosales:Astellas: Employment. Bahceci:Astellas: Employment, Patents Royalties.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results